LONDON--(Marketwire - November 20, 2007) - ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) holds its AGM today. At the meeting, CEO Glyn Edwards will provide an update on the Company’s key pipeline products and other corporate developments:
